NEW YORK, October 19, 2022: Morgan Lewis is representing Advaxis Inc. in its entry into a definitive merger agreement with Ayala Pharmaceuticals Inc.
Advaxis is a biotechnology company devoted to the discovery, development, and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes. Ayala is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.
Partners Robert Dickey and Justin Chairman and associates Samuel Worth, Elizabeth Lee, and Emily Chapman are advising Advaxis.